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Despite improvements in interventions of acute cor-
onary syndromes, primary reperfusion therapies re-
storing blood flow to ischemic myocardium leads to
the activation of signaling cascades that induce cardio-
myocyte cell death. These signaling cascades, includ-
ing the mitogen-activated protein kinase signaling
pathways, activate cardiomyocyte death in response
to both ischemia and reperfusion. We have previously
identified muscle ring finger-1 (MuRF1) as a cardiac-
specific protein that regulates cardiomyocyte mass
through its ubiquitin ligase activity, acting to degrade
sarcomeric proteins and inhibit transcription factors
involved in cardiac hypertrophy signaling. To deter-
mine MuRF1’s role in cardiac ischemia/reperfusion
(I/R) injury, cardiomyocytes in culture and intact
hearts were challenged with I/R injury in the pres-
ence and absence of MuRF1. We found that MuRF1 is
cardioprotective, in part, by its ability to prevent cell
death by inhibiting Jun N-terminal kinase (JNK) sig-
naling. MuRF1 specifically targets JNK’s proximal
downstream target, activated phospho-c-Jun, for deg-radation by the proteasome, effectively inhibiting
downstream signaling and the induction of cell death.
MuRF1’s inhibitory affects on JNK signaling through
its ubiquitin proteasome-dependent degradation of
activated c-Jun is the first description of a cardiac
ubiquitin ligase inhibiting mitogen-activated pro-
tein kinase signaling. MuRF1’s cardioprotection in
I/R injury is attenuated in the presence of pharma-
cologic JNK inhibition in vivo, suggesting a pro-
minent role of MuRF1’s regulation of c-Jun in
the intact heart. (Am J Pathol 2011, 178:1043–1058; DOI:
10.1016/j.ajpath.2010.11.049)
Factors that occlude the coronary arteries, such as
thrombi and acute alterations in atherosclerotic
plaques, result in myocardial ischemia. Advances in
therapeutic interventions that restore the blocked cor-
onary have had profound effects in limiting the size of
the infarct by reducing the amount of frank necrosis in
proportion to how quickly reperfusion takes place.1
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cluding the activation of inflammation and the induction
of apoptosis, it has driven intensive study to identify
mechanisms that could be targeted to reduce the
amount of damage due to therapeutic reperfusion.
The signaling pathways in myocardial ischemia rep-
erfusion injury are complex, redundant, and have not
been fully elucidated. Several pro-apoptotic signaling
pathways have been described in cardiomyocytes.
Myocardial ischemia/reperfusion (I/R) injury activates
mitogen-activated protein kinase (MAPK) signaling
pathways, including the c-Jun N-terminal kinases
(JNK) and the p38 MAPK. The JNK signaling pathway
in particular is activated during ischemia and/or reper-
fusion,2– 8 leading to the induction of apoptosis during
I/R injury.6,9 These findings led to the hypothesis that
inhibiting JNK activity would reduce apoptosis after I/R
injury. Several studies have provided evidence to
prove this concept true by using a nonpeptide ATP
competitive JNK inhibitor10 and a peptide inhibitor of
c-Jun.11 In these studies, inhibition of JNK or the more
specific inhibition of c-Jun was found to be cardiopro-
tective in vivo.
We recently found that muscle ring finger-1 (MuRF1)
blocks pathological cardiac hypertrophy by inhibiting
pro-hypertrophic signaling by directly binding and in-
hibiting the transcription factor serum response fac-
tor.12 We have also found that MuRF1 is necessary for
the development of cardiac atrophy and cardiac hy-
pertrophy reversal.13 MuRF1 is a cardiac ubiquitin ligase
localized to the cytoplasm14 and the M-line of the sarcom-
ere,15 where it targets local proteins such as troponin I,
/slow myosin heavy chain, and myosin binding protein-C
for degradation.16–18 This degradation occurs through the
coordinated placement of polyubiquitin chains on recog-
nized substrates, which are subsequently degraded by the
proteasome.19 MuRF1 exerts its regulation of a number of
cellular processes through its ubiquitin ligase activity and is
involved in monitoring the protein quality control of the car-
diomyocyte.20 While previous studies have identified sev-
eral good candidates using in vitro approaches, the identi-
fication of the physiological in vivo targets of MuRF1 is still
ongoing.
Activation of MAPK signaling pathways occurs in
response to increased oxidative stress, inflammatory
mediators, and stretch, including focal adhesion ki-
nase and stretch activated channels in cardiac myo-
cytes.21 In the present study, we identify a role of cardiac
MuRF1 in the protection against I/R injury by inhibiting JNK
signaling by its specific interaction with and subsequent
degradation of JNK’s proximal effector c-Jun. MuRF1 does
this by preferentially recognizing and ubiquitinating the ac-
tivated (phosphorylated) c-Jun, which is targeted for deg-
radation by the 26S proteasome to effectively inhibit down-
stream signaling. With use of in vivo models of ischemia
reperfusion injury, we identify that increasing MuRF1 inhibits
cardiomyocyte apoptosis induced by I/R injury by blocking
JNK signaling through c-Jun, resulting in significant cardio-
protection. These findings represent a novel mechanism by
which the cardiac ubiquitin ligase MuRF1 coordinates theubiquitin proteasome system to regulate the JNK signaling
pathway in response to stress-mediated stimuli.
Materials and Methods
Animals
The MuRF1 Tg mice used in this study were previously
described.22 All animal protocols were reviewed and ap-
proved by the University of North Carolina Institutional
Animal Care Advisory Committee and were in compli-
ance with the rules governing animal use as published by
the National Institutes of Health.
Plasmids, Antibodies, Chemicals, and
Recombinant Proteins
The full-length and truncated forms of MuRF1 and c-
Jun were generated by PCR and subcloned into mam-
malian expression plasmid pCMV-TB3, pcDNA3.1,
pEGFP-C1, or glutathione S-transferase (GST) fusion
protein expression plasmid pGEX-KG as previously
described.14,16 A luciferase reporter plasmid, AP1-Lu-
ciferase reporter, was from BD Clontech (Palo Alto, CA,
generously provided by Dr. Chiwing Chow). MuRF1
small interfering RNA (siRNA) was generated using BD
knockout RNA interference and cloned into pSIREN
vector as previously described.14 The following pri-
mary and secondary antibodies were used: anti-Flag
(M2, Sigma-Aldrich, St. Louis, MO); anti-HA (12CA5;
Roche Diagnostics Corp., Basel, Switzerland); anti-
GST (Amersham Pharmacia Biosciences, Piscataway,
NJ); anti-Myc (9E10, Santa Cruz Biotechnology Inc.,
Santa Cruz, CA); anti-ubiquitin, anti-His, and anti--actin
(Chemicon International Inc., Temecula, CA); anti-JNK,
anti-phospho-JNK, anti-c-Jun, and anti-phospho-c-Jun
(Cell Signaling Technology, Beverly, MA); and anti-
mouse–conjugated and anti-rabbit–conjugated antibod-
ies (Invitrogen Corp., Carlsbad, CA). Cycloheximide,
MG132, E1, Ubc5C, and ubiquitin were purchased from
Calbiochem (San Diego, CA).
Cell Culture, Transfection, and Luciferase
Assays
HEK293T and the H9C2 cardiomyocyte cell lines were
obtained from American Type Culture Collection (Manas-
sas, VA) and cultured as previously described.23 Cyclo-
heximide and MG132 were added at a final concentration
of 50 g/ml and 10 mol/L, respectively. The luciferase
reporter constructs were co-transfected using Lipo-
fectamine 2000 (Invitrogen Corp.) with expression vec-
tors carrying AP-1-Luc, c-Jun, MuRF-1 WT, and mutants
into HEK293T cells or with MuRF1 siRNAs into H9C2
cells, and luciferase activity was measured as previously
described.23 The data represent the mean  SEM of
three independent experiments run in duplicate and nor-
malized for -gal activity.
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Cells were transduced after 24 hours with adenovirus
and then challenged with a simulated I/R (SI/R) as
previously reported.24 Briefly, cells were placed in an
“ischemia buffer” for 60 minutes in a 5% CO2 to 2% O2
incubator (37°C) containing 118 mmol/L NaCl, 24
mmol/L NaHCO3, 1.0 mmol/L NaH2PO4, 2.5 mmol/L
CaCl2-2H2O, 1.2 mmol/L MgCl2, 20 mmol/L sodium
lactate, 16 mmol/L KCl, and 10 mmol/L 2-deoxyglu-
cose (pH adjusted to 6.2). After 60 minutes, reperfu-
sion was obtained by replacing the ischemic buffer
with Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal bovine serum in a 5% CO2
incubator with room air.
Determination of Cell Death by Trypan Blue,
DNA Fragmentation, TUNEL Staining, and
Cleaved Caspase 3
Cell viability was assessed by trypan blue exclusion
assay and by flow cytometry using the LIVE/DEAD
Fixable Dead Cell Stain Kit (Molecular Probes, Invitro-
gen Corp.) according to the manufacturer’s instruc-
tions. Terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) staining was per-
formed according to the manufacturer’s instructions
(Apoptosis Detection System, fluorescein, catalog
#G3250, Promega, Madison, WI). Western blot analysis
of apoptosis was performed by using an anti-cleaved
caspase-3 (Cell Signaling Technology, Beverly, MA,
Cat, #9661), which recognizes the endogenous levels
of the large fragment (17/19 kDa) of activated caspase
3 resulting from cleavage adjacent to Asp175 as pre-
viously described.24 –26
MAPK Inhibitors
The MAPK inhibitors U0126, SB203580, and SP600125
were used as previously described.27–30
Administration of JNK Inhibitor in Vivo
The JNK inhibitor SP600125 (Anthra[1,9-cd]pyrazol-
6(2H)-one; 1,9-pyrazoloanthrone; SAPK Inhibitor II) was
purchased from EMD Chemicals, Inc. (Calbiochem, La
Jolla, CA, product #420119). SP600125 (6 mg/kg dose
dissolved in 100 L dimethyl sulfoxide) was administered
intraperitoneally to four wild-type and three MuRF1 Tg
mice 2 hours before left anterior descending (LAD) cor-
onary artery ligation and reperfusion as previously de-
scribed.31
Immunoprecipitation, GST Pull-Down, and
Western Blot Assays
Immunoprecipitations and Western blot analysis was per-
formed as previously described.23 Briefly, HEK293T cells
were co-transfected with Myc-MuRF1 and Flag-c-Jun ex-
pression vectors using FuGENE 6 (Roche DiagnosticsCorp.). Tagged proteins were immunoprecipitated for 2
hours at 4°C with either anti-Myc or anti-FLAG using protein
A/G agarose beads, washed, and analyzed by immunoblot-
ting as previously described.23 GST pull-down assays were
performed as described.23 Briefly, HEK293T cells were
transfected with a Flag-c-Jun expression plasmid for 24
hours and then lysed for 30 minutes and pre-cleared with
GST beads for 1 hour. Lysates were then incubated with
either GST or GST-MuRF1 fusion proteins for 1 hour at 4°C.
The bound glutathione-Sepharose beads were then
washed four times with lysis buffer and analyzed by immu-
noblotting as previously described.23
Immunofluorescence
H9C2 cells were cultured and examined for MuRF1 or
c-Jun expression by using immunostaining with anti-
MuRF1 or anti-c-Jun antibodies, respectively, and appro-
priate secondary antibodies. Samples were observed us-
ing confocal microscopy (TCS SP2 laser-scanning
spectral confocal system; Leica Microsystems, Wetzlar,
Germany).
In Vivo Ubiquitination Assays
To assess ubiquitination in vivo, HEK293T cells were
transfected with expression vectors containing His-Ub,
Flag-c-Jun, and Myc-MuRF-1 using FuGENE 6 (Roche
Diagnostics Corp.). Protein lysates were immunoprecipi-
tated and analyzed by Western blot using appropriate
antibodies as previously described.23
Nickel-Agarose Chromatography
HEK293T cells were transfected with His-Ub, Flag-c-
Jun, and Myc-MuRF-1 WT or RING deletion mutant
Myc-MuRF1 (MuRF1  RING) expression plasmids and
lysed in Ni-agarose lysis buffer [50 mmol/L NaH2PO4,
300 mmol/L NaCl, 5 mmol/L imidazole, 0.05% Tween
20, 10 mmol/L N-ethylmaleimide, and Complete Pro-
tease Inhibitor (Roche Diagnostics Corp.)]. His-ubiqui-
tin-conjugated proteins were purified by nickel chro-
matography and subjected to Western blot analysis
using anti-His or anti-Flag antibody as previously de-
scribed.32
In Vitro Ubiquitination Reactions
Ubiquitination reactions in vitro were performed as previ-
ously described.23 Briefly, the reaction mixture (final vol-
ume 30 l) containing 50 mmol/L Tris-HCl (pH 7.4), 5
mmol/L MgCl, 2 mmol/L NaF, 10 nmol/L okadaic acid, 2
mmol/L ATP, 0.6 mmol/L dithiothreitol, 60 ng of E1, 600
ng of Ubc5C, 1 g of purified GST–MuRF1 Wt or RING
deletion mutant, 1 g purified c-Jun, and 10 g of ubiq-
uitin was incubated at 30°C for 2 hours and terminated by
boiling in SDS–sample buffer containing 0.1 M dithiothre-
itol for 5 minutes. Samples were resolved by SDS-poly-
acrylamide gel electrophoresis and analyzed by Western
immunoblot.
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Hearts from MuRF1 Tg and wild-type mice were iso-
lated and perfused as previously described.33–35
Briefly, mice were anesthetized with pentobarbital and
heparinized. Hearts were then quickly removed and
placed in ice-cold buffer, followed by aortic cannula-
tion for retrograde perfusion with a phosphate-free
Krebs-Henseleit buffer (Sigma-Aldrich, K3753) supple-
mented with calcium chloride and sodium bicarbonate
according to the manufacturer’s recommendations.
Cardiac function was followed using a balloon placed
in the left ventricle, monitored using a pressure trans-
ducer, and analyzed using EverBeat system acquisi-
tion software (Mouse Specifics, Inc., Boston, MA). The
hearts were stabilized for a period of at least 20 min-
utes, followed by a 15-minute period of no-flow isch-
emia, followed by a 20-minute period of reperfusion.
Recovery of function was determined as a percentage
of pre-ischemic function.
LAD I/R Injury/Echocardiography
I/R injury was performed by ligation of the LAD coro-
nary artery for 30 minutes, followed by 24 hours of
reperfusion. Briefly, mice were anesthetized with pen-
tobarbital (45 mg/kg), intubated, and placed on a ven-
tilator (tidal volume 200 l, respiratory rate 120/minute,
100% oxygen). The chest cavity was opened by an
incision of the left fourth intercostal space, and the
pericardial sac was removed to visualize the LAD cor-
onary artery. A 7-0 silk suture was passed underneath
the LAD artery 1 to 2 mm below the left auricle and
tied around a 1-mm length of polyethylene tubing
(OD  0.61 mm; Intramedic PE-10, Clay Adams, Par-
sippany, NJ) to produce myocardial blanching and
ECG ST-segment elevation. After 30 minutes, blood
flow was restored and the chest wall was then closed.
Postoperatively, a dose of buprenorphine (0.05 mg/kg)
was given and the mice were allowed to recover at
37°C. Echocardiography on mice was performed at
baseline and after 24 hours of reperfusion on a Visual-
Sonics Vevo 770 ultrasound biomicroscopy system as
previously described.12
Real-Time PCR Analysis of MuRF1 Family
Protein Regulation
Total RNA was isolated from heart using TRIzol reagent
(Invitrogen Corp.) according to the manufacturer’s pro-
tocols. Gene expression studies were performed by a
two-step reaction to determine mRNA expression as pre-
viously described.12,13 The PCR reaction mix included 1
l of mouse-specific TaqMan probes for MuRF1
(Mm01188690_m1), MuRF2 (Mm 01292965_m1), MuRF3
(Mm 00491308_m1), or 18S (Hs99999901_s1) in tripli-
cate (Applied Biosystems, Foster City, CA). Rat MuRF1
(Rn00590197_m1), MuRF2 (Rn01493339_m1), and
MuRF3 (Rn01470046_m1) were assayed in H9C2 cells
and normalized to 18S in a similar manner. The relativeexpression of mRNA was determined using 18S as an
internal sample loading control.
Statistical Analysis
Data are presented as means  SEM. Differences be-
tween groups were evaluated for statistical significance
using Student’s t-test. P values less than 0.05 were re-
garded as significant.
Results
MuRF1 Regulates I/R-Induced Cell Death
and Decreases Phospho-c-Jun Levels in
Cardiomyocytes
We used an adenovirus-dependent gene delivery sys-
tem14 to investigate the effects of MuRF1 on H9C2 car-
diomyocyte viability after SI/R injury. Challenging cardio-
myocytes with a 1-hour simulated ischemia followed by a
24-hour reperfusion induced an approximately 35% de-
crease in control cell viability (Figure 1A). With increased
MuRF1 expression, cardiomyocytes were significantly
protected from SI/R challenge with less than a 20% de-
crease in cell viability. SI/R challenge of H9C2 cells re-
sulted in a parallel increase in apoptosis determined by
TUNEL staining (Figure 1, B and C) and cleaved
caspase-3 activation (Figure 1D). Increased MuRF1 at-
tenuates SI/R-induced TUNEL-positive cells and cleaved
caspase-3 (Figure 1, B–D), indicating its ability to inhibit
apoptotic cell death. Conversely, we found that knocking
down MuRF1 expression in cardiomyocytes with siRNA
significantly enhanced DNA fragmentation after SI/R
challenge (Figure 1E) and TUNEL positive cells (Figure
1F), which is indicative of MuRF1’s role in inhibiting apop-
tosis. MuRF2 mRNA expression, but not MuRF1 and
MuRF3 mRNA expression, was significantly increased
after 24 hours of SI/R (Figure 1G).
We first determined which MAPK signaling pathways
were important in the MuRF1-mediated protection from cell
death in cardiomyocytes induced by SI/R using inhibitors
that targeted extracellular signal-regulated kinase (ERK),
p38, or JNK. Control H9C2 cardiomyocytes (Ad.GFP) and
cells with increased MuRF1 levels (Ad.MuRF1) were chal-
lenged to SI/R in the presence and absence of inhibitors
of ERK, p38, and JNK (Figure 2). By both trypan blue
exclusion (Figure 2A) and TUNEL analysis of cells (Figure
2B), SI/R was shown to enhance cell death by mainly
apoptosis (SI/R). Cells receiving the ERK and p38 inhib-
itors (U0126 and SB203580, respectively) underwent the
same amount of cell death as did SI/R controls, suggest-
ing that these signaling pathways did not play a signifi-
cant role in the SI/R-induced cell death or MuRF1’s car-
dioprotection (Figure 2, A and B). When a JNK inhibitor
(SP600125) was given in parallel studies, significantly
less cell death occurred after SI/R in control cells
(Ad.GFP) and cells with increased MuRF1. This finding
suggests that JNK plays a prominent role in cardiomyo-
cyte SI/R in our model and may be the pathway that
MuRF1 regulates to inhibit SI/R-induced cell death. Ad-
H9C2 ce
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pathway but not the p38 or ERK signaling pathways
comes from Western blot analysis of the ERK, p38, and
JNK pathways after SI/R in the presence of increased
MuRF1 (Figure 2C). The SI/R induced increases in acti-
vated c-Jun (phospho-c-Jun S63 and T91, both neces-
sary for activity).36,37 The SI/R-induced increase in phos-
phorylation c-Jun (p-c-Jun) was attenuated in the
presence of increased MuRF1 (Figure 2C, arrows),
whereas the increased phospho-p38 was unaffected.
This finding confirmed the inhibitor studies that impli-
cated JNK signaling in regulating SI/R-induced cardio-
myocyte cell death. Two possible reasons for this de-
creased c-Jun signaling are that signaling upstream of
c-Jun was being inhibited by MuRF1 or c-Jun itself was
being directly targeted. To delineate where MuRF1 was
acting on JNK signaling, we investigated the activation
of JNK (phospho-JNK), which directly phosphorylates
c-Jun in the JNK signaling pathway. By Western blot
analysis, increased phospho-JNK induced by SI/R was
not affected by increased MuRF1 (Figure 2C). Because
JNK’s most proximal effector c-Jun was decreased,
this finding suggested that MuRF1 inhibited JNK sig-





































































   













































Figure 1. MuRF1 protects against I/R injury–induced cell death. A: Increasin
challenge with 1-hour simulated ischemia (SI) followed by a 24-hour reperf
cells observed by TUNEL assay after SI/R is significantly less with increased
of TUNEL-positive cells was from three independent experiments (120 cells c
to SI/R. Increasing MuRF1 blunted the amount of cleaved caspase-3 determin
of siRNA transfection determined by immunoblot (below) have an enhanc
cytometry. F: An increase in TUNEL-positive cells occurs after cardiomyocyt
of infection for 24 hours, and then treated with normoxia or SI/R for 24
analysis of MuRF1, MuRF2, and MuRF3mRNA expression by RT-PCR in
Ad-GFP or siRNA-control.cytes.Recently, MuRF1 has been identified as a cardiac-
specific ubiquitin ligase, targeting substrates for degra-
dation by the addition of polyubiquitin chains and subse-
quent degradation by the proteasome.14,16,23 We then
explored the possibility that MuRF1 regulated c-Jun by
mediating ubiquitin-dependent degradation. By degrad-
ing c-Jun, MuRF1 might act to inhibit apoptosis by pre-
venting the interaction of phospho-c-Jun with c-Fos to
make up the activator protein-1 (AP-1) transcription factor
to induce apoptosis.38 To begin to delineate this relation-
ship, cardiomyocytes were challenged with SI/R with in-
creasing levels of MuRF1, and phospho-c-Jun was fol-
lowed (Figure 2D) in the presence and absence of the
proteasome inhibitor MG132 (Figure 2E). Increasing
MuRF1 results in a dose-dependent decrease in phos-
pho-c-Jun in SI/R but not in normoxic conditions (Figure
2D), suggesting that MuRF1 degrades the activated form
of c-Jun. To further delineate how MuRF1 may decrease
the activated (phosphorylated) c-Jun, we added the pro-
teasome inhibitor MG132. When MG132 is added to car-
diomyocytes after SI/R, increased MuRF1 no longer de-
creases the activated forms of c-Jun (p-c-Jun S64 and
T91) (Figure 2E). This finding suggests that the degrada-




















































































1 in H9C2 cardiomyocytes using adenovirus protects against cell death after
), determined by trypan blue exclusion. B: The number of apoptotic H9C2
expression as shown in these representative fields. C: Quantitative analysis
per experiment). D: Activated (cleaved) caspase-3 was increased in response
estern immunoblot. E: Cardiomyocytes with decreased MuRF1 after 36 hours
death after SI/R (top) determined by DNA fragmentation analysis by flow
infected with adenovirus siRNA-control or siRNA-MuRF1 at 50 multiplicity
Quantitative analysis was performed as described in C. G: Quantitative











hours.consistent with MuRF1’s role as a ubiquitin ligase. To
convers
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pathophysiologic increases in phospho-c-Jun induced
by SI/R, we knocked down MuRF1 with siRNA in cardio-
myocytes and determined how SI/R stimulated c-Jun ac-
tivation (Figure 2F). Without endogenous MuRF1 to reg-
ulate the increases in phospho-c-Jun (both S64 and T91),
phospho-c-Jun levels were exaggerated compared with
siRNA controls after SI/R (Figure 2F), implicating a role of
endogenous MuRF1s in regulating SI/R-induced in-
creases in p-c-Jun stimulated by SI/R.
MuRF1 Binds to c-Jun to Inhibit Its Cooperative
Transactivation of the AP-1 Transcription Factor
in a Ubiquitin Ligase-Dependent Manner
The AP-1 family of proteins represent sequence-specific
DNA-binding transcription factors formed by homo- and
hetero-dimers of jun (c-jun, junB, and junD) and fos (c-
fos, fra-1, and fra-2) proteins.39 To determine how
MuRF1’s attenuation of phospho-c-Jun affects AP-1 ac-
tivity, the transcriptional activation of AP-1 was deter-
mined in the presence and absence of increased MuRF1
expression (Figure 3A). Increasing MuRF1 expression
Figure 2. MuRF1 protects against ischemia reperfusion injury by inhibiting c
A and B: MuRF1 protects against cell death by inhibiting JNK signaling. H9C2
for 24 hours pretreated with U0126 (MAP kinase/Erk kinase inhibitor, inhib
inhibitor, 10 mol/L) before 30 minutes of simulated hypoxia and 24 hours re
by TUNEL staining (B) and demonstrated that SI/R cell death was mediated
with 50 multiplicity of infection Ad-GFP or Ad-MuRF1, and the effects on
phospho-ERK1/2, total and phospho-p38, total and phospho-JNK1/2, total an
with the indicated antibodies. Only phospho-c-Jun (Ser63 and Thr91) levels
MuRF1 exerts its regulation of cell death by regulating JNK signaling. D: Card
phospho-c-Jun response. E: Parallel studies using the proteasome inhibitor M
is dependent on proteasome degradation. F: Decreasing MuRF1 using siRNA
are expressed as means  SEM, *P  0.01 versus Ad-GFP. IP, immunoprecsignificantly decreased activation of the AP-1 responseelement in cells transfected with AP-1 response element–
luciferase reporter constructs. Previous studies found
that MuRF1’s RING finger domain is the region with ubiq-
uitin ligase activity.16,40 One possible mechanism by
which MuRF1 might inhibit AP-1 activity is through its
interaction and ubiquitination of c-Jun. To test this possi-
bility, we determined how MuRF1 that was missing its
RING finger domain affected AP-1 activity. MuRF1 that
lacked the RING finger domain (with ubiquitin ligase ac-
tivity) did not significantly inhibit AP-1 activity (Figure 3A),
whereas MuRF1 with its intact RING finger intact did. This
finding indicates the dependence of MuRF1’s ubiquitin
ligase activity on its ability to inhibit AP-1 activity. We also
found that activation of the AP-1 construct depended on
c-Jun’s phosphorylation of S63, S73, T91, and T93;
MuRF1’s attenuation of c-Jun activity similarly relied on
c-Jun’s phosphorylation as determined by AP-1 activity
assays using c-Jun phosphorylation mutant constructs
(Figure 3B). In parallel experiments, AP-1 transcriptional
activation was determined after endogenous MuRF1 was
decreased using siRNA (Figure 3C). Consistent with its
role as a ubiquitin ligase recognizing and inhibiting AP-1
activity [specifically activated (phospho-)c-Jun], de-
not the ERK or p38 signaling pathways in a proteasome-dependent manner.
yocytes were infected with 50 multiplicity of infection Ad-GFP or Ad-MuRF1
K1/2, 10 mol/L), SB203580 (p38 inhibitor, 10 mol/L), or SP600125 (JNK
n or normoxia. Cell death was determined by trypan blue exclusion (A) and
ly by the JNK signaling pathway. C: H9C2 cardiomyocytes were transduced
signaling pathways were determined. By Western immunoblot, total and
ho-c-Jun (Ser63 or Thr91), and Myc-MuRF1 were determined by Western blot
ignificantly decreased when MuRF1 expression is increased, indicating that
tes with increasing MuRF1 challenged with SI/R have a blunted or decreased
hours before harvest demonstrated that the blunted phospho-c-Jun response
ely enhances phospho-c-Jun after SI/R challenge in cardiomyocytes. Results
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This finding suggests that endogenous MuRF1 plays a
role in regulating endogenous AP-1 activity in cardiomy-
ocytes.
To build on the evidence that MuRF1 attenuates phos-
pho-c-Jun through its ubiquitin ligase activity, we next
determined whether MuRF1 interacted with c-Jun to af-
fect its activity using GST-MuRF1 pull-down and MuRF1
immunoprecipitation (Figure 3, D and E). When cell ly-
sates from cells transfected with Flag-c-Jun plasmids are
run over a GST-MuRF1 column, MuRF1 is able to specif-
ically pull down c-Jun (Figure 3D). Immunoprecipitation
of MuRF1 similarly pulls down c-Jun specifically in cells
transfected with c-Jun and MuRF1 expression constructs
(Figure 3E), indicating the specificity of the interaction
between c-Jun and MuRF1. The interaction of these two





























































































Figure 3. MuRF1 directly interacts with c-Jun to inhibit transcriptional activit
cells were transfected with luciferase plasmids driven by the AP-1 promoter
necessary for the inhibition of AP-1 activity. B: To assess which c-Jun phosph
and c-Jun mutants were co-transfected in HEK293T cells with the AP-1 lucif
hours. C: To assess how decreasing endogenous MuRF1 affects AP-1 activity,
siRNA MuRF1 oligos, and luciferase activity was determined after 36 hours.
HEK293T cells were transfected with FLAG-cJun and pulled down by GST
confirmed by specific immunoprecipitation of myc-MuRF1 after co-transfectio
co-localization of MuRF1 and c-Jun in cardiomyocytes was identified with u
red), c-Jun (anti-c-Jun/green), and nuclei (DAPI/blue). *P  0.01 versus wiling MuRF1 and c-Jun in the cytoplasm (ie, in a distinctlynon-nuclear distribution) of cardiomyocytes using confo-
cal immunofluorescence (Figure 3F).
MuRF1’s MuRF Family Conserved Region
Interacts with c-Jun
When JNK phosphorylates (activates) c-Jun, phospho-
c-Jun binds fos proteins to act as the transcription
factor AP-1 and induce downstream effectors such as
apoptosis in I/R injury.39,41– 45 Because we determined
that MuRF1 interacts with the c-Jun subunit of the AP-1
complex (made up of jun and fos), we further charac-
terized the regions in which MuRF1 and c-Jun inter-
acted with each other through the use of deletion con-
structs (Figure 4). This characterization was done by
transfecting plasmids with myc-tagged truncated
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assess the role of MuRF1 on phospho-c-Jun transcriptional activity, HEK293T
ated. The ubiquitin ligase activity of MuRF1, found in the RING motif, was
sites were necessary for MuRF1’s inhibition of AP-1 activity, wild-type c-Jun
porter with and without MuRF1. Luciferase activity was determined after 24
rdiomyocytes were co-transfected with AP-1 luciferase, siRNA oligo controls,
etermine whether MuRF1 interacts directly with c-Jun to inhibit its activity,
or GST followed by immunoblot for c-Jun. E: This direct interaction was
c-MuRF1 and FLAG-c-Jun plasmids in HEK293T cells by immunoblot. F: The
nfocal microscopy and immunofluorescent staining of MuRF1 (anti-MuRF1/
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AJP March 2011, Vol. 178, No. 3MuRF1 regions necessary for binding (Figure 4A). Us-
ing deletion constructs, we mapped the sites that
MuRF1 needs to interact with c-Jun to a 42–amino acid
sequence immediately adjacent to the RING finger re-
gion in MuRF1 (Figure 4, A and C). This 42–amino acid
MuRF family conserved (MFC) region is found in all 3
MuRF proteins—MuRF1, MuRF2, and MuRF3.46 Using
MuRF1 pull-down assays, we also identified the region
of c-Jun that was necessary for MuRF1 to interact.
c-Jun deletion constructs were transfected into
HEK293T cells and lysates were applied to a GST-
MuRF1 column. By immunoblotting the proteins eluted
off the GST-MuRF1, we were able to identify the spe-
cific regions of c-Jun necessary for it to bind MuRF1
(Figure 4B). A 95 amino acid region of c-Jun (125-220
a.a.) was identified as necessary for it to interact with
MuRF1 (Figure 4, B and D). While we identified that
MuRF1’s MFC domain interacts with c-Jun’s 125-220
a.a. region, these studies do not exclude the possibility
that additional MuRF1 and c-Jun sequences play a role
Figure 4. MuRF1 binds c-Jun through its MFC domain found in all MuRF fa
was made by co-transfecting FLAG-c-Jun and myc-tagged MuRF1 deletion m
c-Jun that is necessary to bind MuRF1 was determined using GST-MuRF1 fus
of how MuRF1 deletion constructs interacted with c-Jun shows the essential
of pull-down assays demonstrate that the 125-220–amino acid region of c-Jin their interaction.c-Jun Is a Bona Fide Substrate for MuRF1
Ubiquitination
MuRF1’s regulation of AP-1 activity through its RING fin-
ger domain raised the question of whether MuRF1’s ubiq-
uitin ligase activity participated in the targeted degrada-
tion of c-Jun by ubiquitinating it. To answer this question,
we investigated whether MuRF1 ubiquitinates c-Jun in
cell and cell-free systems. Co-transfection of HEK293T
cells with tagged MuRF1, c-Jun, and ubiquitin demon-
strated that increasing MuRF1 levels enhanced c-Jun
ubiquitination (Figure 5A). This enhanced c-Jun ubiquiti-
nation was attenuated when MuRF1 lacking the RING
domain (with its ubiquitin ligase activity) was co-trans-
fected with tagged c-Jun and ubiquitin, indicating the
role of MuRF1’s ubiquitin ligase activity in c-Jun ubiquiti-
nation (Figure 5A). To explore MuRF1’s ubiquitination of
c-Jun in more detail, we investigated MuRF1’s ability to
ubiquitinate c-Jun by determining MuRF1’s ability to
teins. A: The determination of the MuRF1 region that interacted with c-Jun
nd following interactions by immunoprecipitation of c-Jun. B: The region of
ein to pull down c-Jun deletion constructs. C: The schematic representation
f the MFC region for MurF1 to bind c-Jun. D: The schematic representation
cessary for MuRF1 to interact with c-Jun.mily pro
utants a
ion protubiquitinate c-Jun in cell-free systems using purified
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(Figure 5B). MuRF1 polyubiquitinates c-Jun to a much
greater extent than does MuRF1 that is lacking the RING
domain (Figure 5B), indicating that c-Jun is a bona fide
MuRF1 substrate and that MuRF1’s ubiquitin ligase ac-
tivity found in the RING finger domain is responsible for
Figure 5. The ubiquitin ligase activity of MuRF1 promotes mixed chain (K48
and K63) c-Jun ubiquitination in cells and in vitro. A: The RING finger
domain has previously been shown to have ubiquitin ligase activity, which
adds ubiquitin chains to substrates. To determine whether MuRF1’s RING
finger domain was necessary to ubiquitinate c-Jun, HEK293T cells were
co-transfected with c-Jun, MuRF1 (or MuRF1 missing the RING finger do-
main), and His-tagged ubiquitin as indicated. Cell lysates were affinity puri-
fied for ubiquitin using nickel chromatography (which binds His). MuRF1,
but not MuRF1 lacking the RING finger domain, ubiquitinates c-Jun in cells
(top). B: In vitro studies were performed to determine the types of ubiquitin
chains being added to c-Jun by MuRF1. In vitro ubiquitination reactions were
performed with purified ubiquitin, E1, the E2-Ubc5c, purified c-Jun, GST-
MuRF-1 wt or GST-MuRF1RING or GST alone. Immunoblot analysis of ubiq-
uitin demonstrated that MuRF1 enhanced the ubiquitination of c-Jun (left). The
arrow indicates minimum ubiquitination by the MuRF1RING construct.much of MuRF1’s ubiquitination of c-Jun.MuRF1 Preferentially Binds p-c-Jun to
Enhance Its Ubiquitination and Degradation
The protection that cardiac MuRF1 affords occurs in a
very short period after insult (24 hours). This finding
made it necessary to explain how MuRF1 preferentially
decreased c-Jun levels when activated but not before,
at baseline. One possible explanation is that phos-
phorylation of c-Jun enhances its recognition as a
MuRF1 substrate, which has been shown for other
ubiquitin ligases for MAPK signaling substrates.38,47–50
Specifically, JNK itself has ubiquitin ligase activity that
recognizes and degrades phosphorylated c-Jun pref-
erentially.51,52 Therefore, we next determined how c-
Jun’s phosphorylation state changes MuRF1’s affinity,
downstream ubiquitination, and degradation of c-Jun.
Tagged c-Jun, phosphorylation mutant c-Jun con-
structs, and MuRF1 were transfected in HEK293T cells
and immunoprecipitation of MuRF1 was performed to
determine its affinity for the different c-Jun phosphor-
ylation mutants after SI/R (Figure 6A). Despite equal
expression of wild-type c-Jun and phosphorylation mu-
tant c-Jun constructs, MuRF1 bound c-Jun with S63
and S73 mutations with less affinity (Figure 6A), indi-
cating that these phosphorylation sites may be impor-
tant, but not absolutely necessary, for MuRF1 to rec-
ognize c-Jun as a substrate. In parallel experiments,
His-tagged ubiquitin (Ub), MuRF1, and c-Jun phos-
phorylation mutants were transfected into HEK293T
cells, and the amount of c-Jun ubiquitination was de-
termined (Figure 6B). Consistent with MuRF1’s de-
creased affinity for c-Jun with S63 and 73A, decreased
c-Jun ubiquitination was identified on S63 and 73A
c-Jun phosphorylation mutants (Figure 6B). There
seemed to be less dependence on T91 and 93A phos-
phorylation as MuRF1 ubiquitinated the mutant T91,
93A c-Jun to nearly the same levels of wild-type c-Jun.
These findings demonstrate that MuRF1 not only binds
p-c-Jun with greater affinity, but it also ubiquitinates
c-Jun that is phosphorylated at S63 and/or 73A to a
greater extent. This enhanced ubiquitination (found to
be both K48 and K63 linked; data not shown) might
drive the enhanced recognition and degradation by the
proteasome. In this way, MuRF1 preferentially attenu-
ates activated p-c-Jun signaling to quickly counteract
the activating signaling through the JNK/c-Jun signal-
ing pathways when they are activated. Because we
previously identified that MuRF1 degraded p-c-Jun in a
proteasome-dependent manner (Figure 2E), we next
determined if c-Jun phosphorylation was necessary for
its degradation. One way to enhance signaling through
the JNK pathway is to treat cells with cycloheximide,
which results in an increase in phosphorylated c-Jun.
HEK293T cells were transfected with MuRF1 and either
wild-type c-Jun or phosphorylation-resistant c-Jun (c-
Jun S63, 73A, T91 93A) and then challenged with cy-
cloheximide to induce c-Jun phosphorylation (Figure
6C). Wild-type c-Jun is rapidly degraded between 1
and 6 hours after cycloheximide treatment; however,
the degradation of the phosphorylation mutant c-Jun in
1052 Li et al
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These studies are consistent with a role of MuRF1 in
preferentially ubiquitinating activated (phosphory-
lated) c-Jun and targeting it for degradation by the 26S
proteasome to attenuate AP-1 (c-Jun/fos) activity. In
this way MuRF1 acts as a negative feedback mecha-
nism to ensure that JNK signaling, leading to cell
death, is attenuated during stresses such as I/R injury.
This process allows a mechanism for cardiac JNK sig-
naling to be kept in check to balance and control the
necessary signaling pathways activated during car-
diac stress.
Increased Cardiac MuRF1 Protects Against I/R
Injury and Decreases Steady-State Proteins
Levels of Phospho-c-Jun in Vivo
To test the relevance of our observations in the intact
heart, we examined the effects of MuRF1 on cardiac I/R
injury in transgenic (Tg) mice that have an increased
cardiac MuRF1 as recently reported by our labora-
tory.22 Our in vivo studies focus on the MuRF1 Tg
mice because of the reported redundancy of MuRF1with other MuRF family members (MuRF2 and MuRF3)
in the heart.17,53,54 Additionally, our in vitro studies
identified that MuRF1 interacted with c-Jun through its
MFC region, which is a region with a high degree of
homology found in MuRF1, MuRF2, and MuRF3. Mice
lacking MuRF1 and MuRF253 or MuRF1 and MuRF317
have severe phenotypes that limit their use in I/R stud-
ies. We challenged MuRF1 Tg mice to two models of
cardiac ischemia reperfusion injury: (1) transient global
ischemia (15 minutes) followed by 20 minutes of rep-
erfusion (ex vivo); and (2) 30-minute ligation of the LAD
coronary artery followed by 24 hours reperfusion (in
vivo). Baseline function determined on the isolated
MuRF1 Tg heart function (eg, developed pressure
per time) was not significantly different from wild-type
hearts by isovolemic pressure determination of the iso-
lated heart (see Supplemental Table S1 at http://ajp.
amjpathol.org), consistent with previous catheterization
studies of the MuRF1 Tg mice.22 In response to
global ischemia followed by reperfusion in isolated
hearts, MuRF1 Tg hearts recovered function to a
greater degree in ex vivo studies as evidenced by
Figure 6. MuRF1 preferentially binds, ubiquitinates, and de-
grades phosphorylated c-Jun. A: HEK293T cells were co-trans-
fected with plasmids expressing MuRF1, c-Jun, and phosphoryla-
tion site c-Jun mutants. Interactions between MuRF1 and the
different phosphorylation mutants were determined by immuno-
precipitation. MuRF1 (anti-myc) immunoprecipitation bound wild-
type c-Jun preferentially to c-Jun that was unable to be phosphor-
ylated at S63 and 73A determined by immunoblot for c-Jun
constructs (anti-FLAG). B: MuRF1’s preferential binding of wild
type c-Jun compared with S63, 73A mutants parallels MuRF1’s
ubiquitination of c-Jun. HEK293T cells co-transfected with plasmids
expressing His-Ub, Myc-MuRF1, and Flag-c-Jun wild-type or c-Jun
phosphorylation mutants as indicated. c-Jun was immunoprecipi-
tated and ubiquitination was determined by immunoblot (top),
despite equal expression of c-Jun and c-Jun mutants (bottom).
c-Jun mutants lacking their S63, S73 phosphorylation sites are
ubiquitinated less by MuRF1 in response to JNK stimulation. C:
MuRF1 preferentially degrades c-Jun after its phosphorylation in
response to cycloheximide. HEK293T cells were transfected with
MuRF1, wild-type c-Jun, and a mutant c-Jun that was unable to be
phosphorylated (c-Jun S63, 73A, T91, 93A). By immunoblot, only
the wild-type c-Jun that can be phosphorylated is degraded by
MuRF1.recovery of left ventricular developed pressure (Figure
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org). No differences in % decline and contracture time
were identified between MuRF1 Tg and wild-type
hearts (data not shown), indicating that increasing car-
diac MuRF1 did not affect the way Ca2 was handled
during I/R.55
The MuRF1 Tg mice also were protected against
ischemia-reperfusion injury in vivo. The cardiac func-
tion (fractional shortening) in wild-type hearts de-
creased 47.6% 24 hours after I/R injury (Figure 7B,
top). MuRF1 Tg hearts, however, only had a 6.9%
decrease in function after I/R injury (Figure 7B, top).
Consistent with this protection, MuRF1 Tg hearts did
not dilate after I/R as much as did wild-type mice (see
Supplemental Table S2 at http://ajp.amjpathol.org).
MuRF1 Tg hearts were not only functionally pro-
tected, but they had a smaller infarction (measured as
a percentage of area at risk) compared with wild-type
mice by histology (Figure 7B, bottom). Whereas wild-
type hearts had an infarct area of 25% (measured as
a percentage of the area at risk), MuRF1 Tg hearts
had an infarct of only 10% (Figure 7B, bottom). These
results are consistent with our in vitro studies where
increasing MuRF1 protects cardiomyocytes from I/R-
induced cell death (Figure 1). Because the mechanism
of this protection was attributed to the targeted degra-
dation of p-c-Jun in our in vitro studies, we next inves-
tigated this mechanism in MuRF1 Tg hearts in vivo
after I/R injury. In contrast to our in vitro studies, I/R
injury in MuRF1/ mice (previously described by our
laboratory)12,13 did not significantly differ at 24 hours
(see Supplemental Figure S1 and Supplemental Table
S1 at http://ajp.amjpathol.org). This finding may be due
to the functional redundancy of MuRF1 and
MuRF2,54,56 supported by the finding that c-Jun is
bound by MuRF1 through its MFC regions, which all
family members share.
Because phospho-c-Jun was recognized preferen-
tially by MuRF1 as a substrate, we investigated both
total c-Jun and phospho-c-Jun levels in MuRF1 Tg
and wild-type hearts 24 hours after LAD I/R injury. We
found that the MuRF1 Tg hearts had decreased
phospho-c-Jun 24 hours after reperfusion (Figure 7C,
bottom). These differences were not due to differences
in the steady-state levels of total c-Jun or phospho-c-
Jun found in unchallenged age-matched control hearts
(Figure 7C, top). Additionally, we did not identify dif-
ferences in total or phospho-JNK protein by Western
immunoblot, suggesting that the inhibition of phospho-
c-Jun was not due to the inhibited signaling upstream
of JNK but at the level most proximal to JNK—at the
level of c-Jun— consistent with our findings in vitro. We
also found that the total c-Jun levels decreased after
I/R injury in the MuRF1 Tg hearts. No differences in
phospho-ERK1/2 or phospho-p38 were identified be-
tween MuRF1 Tg hearts and wild type at baseline or
after 24 hours I/R (Figure 7D). Cleaved caspase 3 by
Western blot was decreased after I/R, consistent with
the cardioprotection and decreased area of infarction
identified in these mice (Figure 7D).MuRF1, MuRF2, and MuRF3 Levels Do Not
Significantly Change After Cardiac I/R Injury in
Wild-Type Mice
Understanding the regulation of MuRF1 during isch-
emia reperfusion would give context to the mecha-
nisms by which MuRF1 protects in wild-type mice. We
determined MuRF1 (as well as MuRF2 and MuRF3)
mRNA levels in the nonischemic regions in wild-type
hearts and found that it did not change significantly 24
hours after I/R in wild-type hearts (Figure 7E). Recent
studies investigating how MuRF1 is regulated in human
myocardial infarction have identified that MuRF1 sig-
nificantly decreases in the weeks following insult (2
weeks).57 When rats undergo myocardial infarction in-
duced by a static LAD artery ligation, MuRF1 has been
found to increase at the 7-week time point,58 suggest-
ing that the regulation of MuRF1 may be dynamic in the
remodeling process, in part to deal with the changing
MAPK signaling pathways.
Pretreatment of MuRF1 Tg Mice With a JNK
Inhibitor Abolishes the Differential
Cardioprotection of Cardiac MuRF1
To determine the significance of JNK signaling in our in
vivo model and its role in MuRF1’s cardioprotection, we
pretreated MuRF1 Tg and sibling wild-type control mice
with the JNK inhibitor SP600125, as previously described
in vivo 31 (Figure 7F). Both wild-type and MuRF1 Tg
hearts demonstrated an 10% infarction size when pre-
treated with the JNK inhibitor (Figure 7F) compared with
the 25% infarction size seen in wild type (Figure 7B).
Functionally, MuRF1 Tg hearts decreased to the same
extent as wild-type hearts (Figure 7B; see Supplemental
Table S3 at http://ajp.amjpathol.org).
Discussion
The susceptibility of cardiomyocytes to cell death during
I/R injury depends, in part, on cell signaling processes
that induce cell death. The signaling pathways most com-
monly implicated in this process are the MAPK pathways,
in particular the p38 and JNK pathways.6,9 The signifi-
cance of JNK-induced apoptosis in cardiomyocyte I/R
injury is highlighted by successful attempts at pharma-
cologically blocking JNK pathways in experimental car-
diac I/R injury to reduce cell death.8,10,11,59 Inhibition of
JNK signaling in a number of other organs is protective
against I/R injury, including the brain,60 lung,61 kidney,6
and liver.62 In the present study, we identified a novel
endogenous cardiac protein (MuRF1) that inhibits JNK
signaling by the directed ubiquitination and degradation
of activated (phosphorylated) c-Jun to inhibit down-
stream AP-1 signaling. In this manner, MuRF1 appears to
act as a constitutive disposal mechanism by which JNK
signaling is buffered by its recognition and destruction of
the activated (phosphorylated) c-Jun. These findings
compliment our recent studies identifying MuRF1 as an
1054 Li et al




































MuRF1 Tg+ Global I/R Injury in isolated heart MuRF1 Tg+ LAD occlusion I/R Injury in vivo












































37   
37   
53   
37   
53   
Wild Type MuRF1 Tg+



































































































Wild Type Wild Type 
E F MuRF1 Tg+ LAD occlusion I/R Injury in vivo
























  Baseline               MuRF1 +/+             MuRF1 Tg+
+dP/dt max      1677.7 +/- 376.4       1941.5 +/- 574.2
-dP/dt max       -1094.5 +/- 257.6      -1478.8 +/- 420.4
*
*
20 Min Post R               MuRF1 +/+             MuRF1 Tg+
   +dP/dt max              725.5 +/- 40.6        1039.9 +/- 326.1

























































MuRF1 Tg+ LAD Occlusion I/R injury in vivo
Figure 7. Mice with increased cardiac MuRF1 exhibit attenuated I/R injury and have an enhanced degradation of cardiac c-Jun in response to I/R in vivo. A: Isolated working
hearts from MuRF1 Tg and strain-matched wild-type mice were assayed at baseline and after global I/R injury on a Langendorff system. Hearts were allowed to equilibrate for
at least 30 minutes, followed by 15 minutes of no-flow ischemia and 20 minutes reperfusion. The recovery of cardiac function (expressed as a % of baseline function) is the fraction
of mean left ventricular developed pressure. MuRF1 Tg heart recovery trended to improve 20 minutes after perfusion was restarted. (Additional functional parameters are shown
in Supplemental Table S1 at http://ajp.amjpathol.org. N  5 to 6 per group outlined in Supplemental Table 1 at http://ajp.amjpathol.org). *P  0.05. B: To determine the durability
of this recovery, we challenged MuRF1 Tg mice to a 30-minute LAD ischemia injury, followed by a 24-hour recovery in vivo. Determination of the areas of infarct as a fraction
of the area at risk demonstrated that MuRF1 Tg mice had significant protection against I/R injury in vivo (top). Conscious echocardiography was performed to determine the
functional protection of cardiac MuRF1 to I/R injury in vivo. MuRF1 Tg mice had significantly less functional deficit compared with wild-type mice determined by fractional
shortening (bottom) and EF% (see Supplemental Table S2 at http://ajp.amjpathol.org. N  6 to 12 mice per group outlined in Supplemental Table S2 at http://ajp.amjpathol.org).
Arrows indicate infarcted area in white. C: Cardiac c-Jun and phospho-cJun in MuRF1 Tg and wild-type hearts 24 hours after LAD I/R injury were determined by immunoblot.
Significantly less c-Jun and phospho-c-Jun were found in four representative hearts consistent, with its role as a MuRF1 substrate in vivo. N  3 to 4 hearts per group as indicated
in blot. PhosphoSer63-c-jun/total c-jun ratio is the density of the phosphoSer63 c-jun (A.U.) divided by the density of total c-jun (A.U.) to determine the relative phosphorylation
of c-jun site associated with activation. D: Cardiac cleaved caspase-3, phospho-ERK1/2/total ERK1/2, phospho-p38/total p38 at baseline and after 30 minutes ischemia and 24
hours reperfusion. E: Real-time PCR analysis of cardiac MuRF1, MuRF2, and MuRF3 mRNA in sham or I/R-challenged wild-type mice 24 hours after surgery. F: Histologic
evaluation of cardiac infarction and cardiac function in MuRF1 Tg hearts pretreated with the JNK inhibitor SP600125 and challenged with I/R injury (further echocardiographic
detail can be found in Supplemental Table S3 at http://ajp.amjpathol.org). *P  0.05, ***P  0.001.
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factors, including serum response factor, during patho-
logical cardiac hypertrophy.12
In the current study, we found that MuRF1 Tg and
wild-type cardiac function is not different in the isolated
heart. However, we found that by conscious echocardi-
ography we can detect a mild decrease in baseline car-
diac function in MuRF1 Tg hearts compared with sibling
wild-type mice, which is evident by decreases in the
fractional shortening (Figure 7B) and ejection fraction
(see Supplemental Table S2 at http://ajp.amjpathol.org).
We believe this apparent deficit is due to the stress in-
volved with conscious echocardiography, because iso-
lated heart studies in the present study did not detect a
functional defect as demonstrated by  developed pres-
sure per time (see Supplemental Table S1 at http://ajp.
amjpathol.org). Studies inhibiting JNK signaling in the
MuRF1 Tg mice before I/R demonstrated a reduction in
this deficit by conscious echocardiography (Figure 7F;
see Supplemental Table S3 at http://ajp.amjpathol.org).
Despite the complex MuRF1 Tg cardiac phenotype,
MuRF1’s cardioprotection is due, in part, to its regulation
of JNK signaling, as these in vivo correlates of our in vitro
findings suggest.
Our previous evaluation of the MuRF1 Tg mice dem-
onstrated that in the face of pressure overload, MuRF1
Tg hearts were more susceptible to failure.22 We found
that creatine kinase (CK) activity was decreased, which
we hypothesized had to do with the possible turnover of
CK. When CK isoenzymes are deleted from the heart,
there are serious consequences to cardiac energetics.
When the muscle (M) and mitochondrial (Mt) isoforms are
deleted, CK/ mice have an ATP synthesis rate of
9%.63 Inhibiting the flux of phospho-creatinine, the inter-
mediate regulated by CK, either pharmacologically or
genetically, enhances the mortality and loss of ATP in the
face of myocardial infarction.64,65 These studies demon-
strate the importance of CK in ischemic injury; however,
the MuRF1 Tg hearts do not have a deficit in function
after I/R injury. There is not a reason to believe, then,
that MuRF1’s affects on CK activity would be respon-
sible for protecting against I/R injury. However, we also
believe that MuRF1’s inhibition of JNK signaling (via
c-Jun) is just one mechanism by which our MuRF1 Tg
mouse model is protected in I/R and that other mech-
anisms have yet to be identified.
In response to coronary artery occlusion and I/R
injury, cell death occurs by multiple cell death path-
ways, including apoptosis and necrosis, and has been
associated with autophagy.66 In our in vitro systems,
we see that much of the observed cell death can be
detected by TUNEL staining, which can be increased
in apoptosis. However, TUNEL staining also can detect
changes seen with necrosis and other repair mecha-
nisms, whereby necrosis initiates some of the apopto-
sis machinery.67,68 This finding might explain the ap-
parent disconnect in our in vitro studies and our in vivo
studies, because our in vivo studies demonstrate little
cleaved caspase 3 protection in MuRF1 Tg hearts
(Figure 7E), in contrast with the considerable protec-
tion from infarction histologically (Figure 7E). Thesefindings support the growing appreciation for the role
of necrosis in I/R injury. While much has been studied
on cell death and apoptosis that is activated by MAPK
signaling, including JNK,6,9 newer studies have found
that apoptosis is not the only downstream process that
MAPK signaling regulates. Pro-survival pathways also
are stimulated by MAPK,69,70 including JNK in the face
of particular cardiomyocyte stresses,71 including reac-
tive oxygen species.72 Careful consideration of these
alternative pro-survival MAPK signaling pathways should
be made when determining the benefits of inhibiting spe-
cific pathways.
In the present study, we identified that MuRF1 inter-
acted with c-Jun through its MFC region.46 The MFC is
a highly conserved region in MuRF1, MuRF2, and
MuRF3 proteins, suggesting that any of these proteins
may regulate c-Jun. We believe it is because of this
redundancy that we were unable to identify any phe-
notype in MuRF1/ mice (see Supplemental Figure
S1 and Supplemental Table S4 at http://ajp.amjpathol.
org), but we could in the MuRF1 Tg mice. Given the
complex phenotype and developmental defects found
in MuRF1/3 and MuRF1/2 double-null mice, further
testing of this hypothesis was not feasible in vivo. This
redundancy does not seem to apply to our H9C2 cell
culture model, where siRNA MuRF1 enhanced SI/R cell
death. Differences between the MuRF1/ mice and
the MuRF1 siRNA in H9C2 cells may be explained by
the differential regulation of these complimentary
MuRF family proteins. In the intact mouse heart,
MuRF1, MuRF2, and MuRF3 do not change after I/R
(Figure 7E), whereas MuRF2 is significantly increased
in the rat H9C2 cells after SI/R (Figure 1G). There may
even be regional differences in MuRF1 activity, be-
cause the H9C2 cells are atrial cardiac derived cells
and the experiments in the intact mouse hearts only
look at ventricular responses. More work is needed to
completely understand the interplay of the MuRF family
proteins and their regulation in I/R injury, which may be
species and/or cell type specific.
After 24 hours of I/R injury, hearts from MuRF1 Tg
mice had a decrease in total c-Jun compared with
baseline. This finding was different from our in vitro
studies in which total c-Jun levels were unaffected by
increases in MuRF1. One explanation for this may be
the differences in the magnitude of MuRF1 expression
in the two systems or the amount of c-Jun that was
activated/phosphorylated by the different models of
stress. The MuRF1 Tg hearts have a 45-fold increase
in endogenous MuRF1, which is considerably more
than could be achieved in our in vitro systems. This
enhanced ubiquitin ligase (MuRF1) expression may
lead to greater ubiquitination of the phosphorylated
c-Jun, which degrades a greater proportion of the total
c-Jun. Our in vivo I/R injury also may enhance c-Jun
phosphorylation to a much greater extent because it is
a no-flow ischemic event, making it preferentially ubiq-
uitinated and targeted for degradation. Either way,
these findings are consistent with the mechanisms we
identified in our in vitro studies, where I/R injury induces
c-Jun phosphorylation, making it a substrate for
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AJP March 2011, Vol. 178, No. 3MuRF1, which then ubiquitinates it, targeting it for deg-
radation by the proteasome. Because JNK signaling
through c-Jun is responsible for activating cell death
pathways, the cardioprotection afforded the MuRF1
Tg hearts may be due, in part, to the inhibition of JNK
signaling we identified. Experimentally, inhibiting c-Jun
NH2 terminal kinase (JNK) signaling significantly re-
duces cardiac I/R injury and infarct size in vivo,10,11,59
indicating JNK’s key role in mediating I/R injury. How-
ever, MuRF1 interacts with a host of substrates that
regulate protein turnover and metabolism, so MuRF1’s
inhibition of JNK signaling may only partially explain its
cardioprotective mechanisms in vivo.
Previous studies mapping MuRF1’s interaction with
its substrates have identified several unique regions.
MuRF1’s interaction with troponin I occurs through the
coiled-coil region,16 whereas the interaction with mus-
cle CK occurs through its B-box region.73 This finding
contrasts with that of the present study, which found
that MuRF1 binds c-Jun by its MFC region, a region
with nearly complete homology between MuRF1,
MuRF2, and MuRF3.46 MuRF1, MuRF2, and MuRF3 are
all found in close proximity to each other in the cardi-
omyocyte sarcomere and cytoplasmol.14,15,46 Recent
studies highlight how MuRF1 may be redundant with
the remaining members MuRF2 and MuRF3.17,53,54
Both MuRF1 and MuRF2 interact with a specific subset
of myofibrillar proteins,54 as do MuRF1 and MuRF3.17
Studies knocking out more than one of the MuRF family
members demonstrate hypertrophy and cardiomyopa-
thy (MuRF1/MuRF2 DKO)53 and cardiomyopathy with
an increased susceptibility to myocardial infarction
(MuRF1/MuRF3 DKO),17 making compound knock-outs
impractical to use. It is for this reason that we per-
formed our in vivo experiments in the cardiac MuRF1
Tg mice, which allowed us to delineate MuRF1’s role
in the heart, despite the apparent redundancy between
the MuRF family members in the heart.
MuRF1 interacts with many proteins and transcrip-
tion factors to regulate the turnover of the sarcomere,20
pressure overload–induced cardiac hypertrophy,12
and cardiac atrophy.13 The findings in the present
study suggest that MuRF1 preferentially recognizes,
ubiquitinates, and degrades phosphorylated c-Jun to
regulate its activity to fundamentally regulate, in part,
the pathophysiology of I/R injury. However, the down-
stream cardioprotection seen in our in vivo experiments
may be due only in part to the inhibition of JNK signal-
ing. To fully understand how MuRF1 might be cardio-
protective in ischemia reperfusion injury, we will need
to understand more fully the spectrum of mechanisms
by which MuRF1 protects the heart in vivo.
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